Lawyers for patients suing Johnson & Johnson and Bayer allege that the companies misled editors at The New England Journal of Medicine about the safety of rivaroxaban (Xarelto), the New York Times reports.
The attorneys allege that Duke University researchers left out critical laboratory data. Johnson & Johnson and Duke said they worked independently, while Bayer declined to comment. Sales of rivaroxaban, an oral anticoagulant, were nearly $2 billion in the U.S. last year.
Click below for the full story: